Pazopanib: A review of its use in the management of advanced renal cell carcinoma

Drugs

Volumn 74, Issue 10, 2014, Pages 1111-1125

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

PAZOPANIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADVANCED CANCER; ANGIOGENESIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CANCER SURVIVAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NONHUMAN; PATIENT PREFERENCE; PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; KIDNEY NEOPLASMS; METABOLISM; PATHOLOGY;

PISCES;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; HUMANS; KIDNEY NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUALITY OF LIFE; SULFONAMIDES;

EID: 84903895096     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0243-3     Document Type: Article

References (50)

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2014. http://globocan.iarc.fr/. Accessed 20 May 2014.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335(12):865-75.
3. Ljungberg B, Campbell SC, Cho HY, et al. The epidemiology of renal cell carcinoma. Eur Urol. 2011;60(4):615-21.
4. Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma. 2013. http://www.uroweb.org/gls/pdf/10-Renal-Cell-Carcinoma-LRV2.pdf. Accessed 20 May 2014.
5. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs. 2011;71(9):1179-91.
6. Zacchia M, Vilasi A, Capasso A, et al. Genomic and proteomic approaches to renal cell carcinoma. J Nephrol. 2011;24(2):155-64.
7. Pfaffenroth EC, Linehan WM. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther. 2008;8(6):779-90.
8. Allory Y, Culine S, de la Taille A. Kidney cancer pathology in the new context of targeted therapy. Pathobiology. 2011;78(2):90-8.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer (version 3.2014). 2014. http://www.nccn.org/ professionals/physician-gls/pdf/kidney.pdf. Accessed 22 May 2014.
10. Escudier B, Eisen T, Porta C, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii65-71.
11. European Medicines Agency. Votrient (pazopanib) 200 mg film-coated tablet: summary of product characteristics. 2013. http://www.ema.europa.eu/docs/ en-GB/document-library/EPAR-Product-Information/human/001141/WC500094272.pdf. Accessed 20 May 2014.
12. GlaxoSmithKline. Votrient (pazopanib) tablets: US prescribing information. 2013. http://us.gsk.com/products/assets/us-votrient.pdf. Accessed 20 May 2014.
13. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011;71(4):443-54.
14. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007;6(7):2012-21.
15. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer. 2009;101(10):1717-23.
16. Canter D, Kutikov A, Golovine K, et al. Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines. Can J Urol. 2011;18(4):5819-25.
17. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827-37.
18. Xu C-F, Bing NX, Ball HA, et al. Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol. 2011;29(18):2557-64.
19. Xu C-F, Reck BH, Goodman VL, et al. Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol. 2011;54(6):1237-43.
20. Xu C-F, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer. 2010;102(9):1371-7.
21. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors. Clin Pharmacol Ther. 2010;88(6):818-23.
22. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res. 2009;15(12):4220-7.
23. FDA Center for Drug Evaluation and Research. Votrient (pazopanib) hydrochloride tablets: clinical pharmacology and biopharmaceutics review(s). 2009. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2009/022465s000- ClinPharmR.pdf. Accessed 20 May 2014.
24. Xu C-F, Xue Z, Bing N, et al. Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancer. Ann Oncol. 2012;23(9):2470-1.
25. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061-8.
26. Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol. 2014;32(14):1412-8.
27. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-31.
28. Sanford M, Keating GM. Pazopanib: in advanced renal cell carcinoma. BioDrugs. 2010;24(5):279-86.
29. Hutson TE, Davis ID, Machiels J-PH, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010;28(3):475-80.
30. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287-96.
31. Hawkins RE, Hong SJ, Ulys A, et al. An open-label extension study to evaluate safety and efficacy of pazopanib in patients with advanced renal cell carcinoma (RCC) [abstract no. 5110]. J Clin Oncol. 2009;27(15 Suppl).
32. Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769-70.
33. Cella D, Pickard AS, Duh MS, et al. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial. Eur J Cancer. 2012;48(3):311-23.
34. Goodman V, Wang K, Pandite L, et al. Incidence and management of hepatic toxicity in pazopanib-treated patients [abstract no. 904P]. Ann Oncol. 2010;21(Suppl 8):viii282.
35. Lim FL, Shamash J, Wilson P, et al. Liver toxicity in patients with metastatic renal cell carcinoma treated with pazopanib therapy [abstract no. 880]. Ann Oncol. 2012;23(Suppl 9):ix290.
36. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. http://ctep.cancer. gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf. Accessed 20 May 2014.
37. Pal SK, Vanderwalde A, Hurria A. Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging. 2011;28(8):635-49.
38. Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alfa therapy. Pharm World Sci. 2005;27(6):423-31.
39. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90.
40. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-11.
41. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422-8.
42. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-81.
43. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.
44. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-56.
45. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931-9.
46. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III Treatment Approaches in Renal cancer Global Evaluation Trial. J Clin Oncol. 2009;27(20):3312-8.
47. McCann L, Amit O, Pandite L, et al. An indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC) [abstract no. e15128]. J Clin Oncol. 2010;28(15 Suppl).
48. Mickisch GH, Schwander B, Escudier BJ, et al. Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy [abstract no. 4612]. J Clin Oncol. 2010;28(15 Suppl).
49. Garnick MB. How to interpret patient preferences in selecting the best drug: are the current measurements up to the job? J Clin Oncol. 2014;32(14):1392-3.
50. Kilonzo M, Hislop J, Elders A, et al. Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a NICE single technology appraisal. Pharmacoeconomics. 2013;31:15-24.